Jaume Capdevila

6.2k total citations
127 papers, 1.9k citations indexed

About

Jaume Capdevila is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Jaume Capdevila has authored 127 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 40 papers in Epidemiology and 28 papers in Surgery. Recurrent topics in Jaume Capdevila's work include Colorectal Cancer Treatments and Studies (54 papers), Neuroendocrine Tumor Research Advances (39 papers) and Lung Cancer Research Studies (32 papers). Jaume Capdevila is often cited by papers focused on Colorectal Cancer Treatments and Studies (54 papers), Neuroendocrine Tumor Research Advances (39 papers) and Lung Cancer Research Studies (32 papers). Jaume Capdevila collaborates with scholars based in Spain, United States and Palestinian Territory. Jaume Capdevila's co-authors include Josep Tabernero, Francisco Javier Ramos, Élena Elez, Teresa Macarulla, Bengt Glimelius, Andrés Cervantes, Ben Markman, Gina Brown, Andrew Wotherspoon and Ian Chau and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Jaume Capdevila

119 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jaume Capdevila Spain	20	1.4k	644	379	349	264	127	1.9k
Matias Riihimäki Sweden	12	1.4k 1.0×	460 0.7×	821 2.2×	348 1.0×	378 1.4×	12	2.2k
C.J. van Groeningen Netherlands	22	1.1k 0.8×	1.0k 1.6×	590 1.6×	522 1.5×	222 0.8×	49	2.4k
Lorenzo Antonuzzo Italy	23	1.3k 0.9×	264 0.4×	609 1.6×	329 0.9×	404 1.5×	173	1.9k
Kenjiro Kotake Japan	26	1.9k 1.3×	993 1.5×	771 2.0×	266 0.8×	357 1.4×	116	2.6k
H. D. Saeger Germany	22	1.1k 0.7×	593 0.9×	341 0.9×	815 2.3×	325 1.2×	63	2.2k
Osama E. Rahma United States	28	2.1k 1.5×	315 0.5×	520 1.4×	485 1.4×	371 1.4×	113	2.9k
Shigenobu Emoto Japan	24	749 0.5×	894 1.4×	534 1.4×	255 0.7×	195 0.7×	182	1.8k
Ammar Sukari United States	24	1.5k 1.1×	311 0.5×	635 1.7×	640 1.8×	255 1.0×	118	2.3k
Ulf Petrausch Switzerland	23	1.1k 0.8×	231 0.4×	289 0.8×	289 0.8×	105 0.4×	62	1.6k
Randeep Sangha Canada	23	1.3k 0.9×	376 0.6×	542 1.4×	590 1.7×	136 0.5×	72	2.3k

Countries citing papers authored by Jaume Capdevila

Since Specialization

Citations

This map shows the geographic impact of Jaume Capdevila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Capdevila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Capdevila more than expected).

Fields of papers citing papers by Jaume Capdevila

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaume Capdevila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Capdevila. The network helps show where Jaume Capdevila may publish in the future.

Co-authorship network of co-authors of Jaume Capdevila

This figure shows the co-authorship network connecting the top 25 collaborators of Jaume Capdevila. A scholar is included among the top collaborators of Jaume Capdevila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaume Capdevila. Jaume Capdevila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cercek, Andrea, Jean‐Baptiste Bachet, Jaume Capdevila, et al.. (2025). A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1). Clinical Colorectal Cancer. 24(2). 325–330.

Capdevila, Jaume, Holger Amthauer, Hein J. Verberne, et al.. (2025). 1706O Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase III COMPETE trial. Annals of Oncology. 36. S941–S941. 1 indexed citations

Navarro, Vı́ctor, Marta Ligero, Alonso García-Ruiz, et al.. (2024). Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer. Radiology Artificial Intelligence. 6(2). e230118–e230118. 15 indexed citations

Martínez, María Carmen Riesco, Jaume Capdevila, Vicente Alonso, et al.. (2024). Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913). Nature Communications. 15(1). 6753–6753. 10 indexed citations

García‐Carbonero, Rocio, Paula Jiménez‐Fonseca, Urbano Anido, et al.. (2024). ¹⁷⁷Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.. Journal of Clinical Oncology. 42(16_suppl). TPS3177–TPS3177.

Romesser, Paul B., Jaume Capdevila, Rocio García‐Carbonero, et al.. (2023). A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical Cancer Research. 30(4). 695–702. 17 indexed citations

Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2023). Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival. European Journal of Endocrinology. 190(1). 62–74. 6 indexed citations

Capdevila, Jaume, Ismael Macías, Ignacio Escobar, et al.. (2023). Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.. Journal of Clinical Oncology. 41(16_suppl). TPS3624–TPS3624.

Arqués, Oriol, Irene Chicote, Lorena Ramírez, et al.. (2023). DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype. Cell Reports. 42(8). 112927–112927. 4 indexed citations

10.

Capdevila, Jaume, David Páez, Carles Pericay, et al.. (2022). SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Clinical & Translational Oncology. 24(4). 646–657. 9 indexed citations

11.

Cubero, Jorge Hernando, et al.. (2021). Drug Development in Neuroendocrine Tumors: What Is on the Horizon?. Current Treatment Options in Oncology. 22(5). 43–43. 8 indexed citations

12.

Capdevila, Jaume, Àlex Teulé, Carlos López, et al.. (2020). 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Annals of Oncology. 31. S770–S771. 37 indexed citations

13.

Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2020). 1159MO Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE). Annals of Oncology. 31. S772–S772. 1 indexed citations

14.

Matos, Ignacio, María Vieito, Irene Braña, et al.. (2020). 572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials. Annals of Oncology. 31. S489–S489. 1 indexed citations

15.

Valk, Maxime J.M. van der, Corrie A.M. Marijnen, Boudewijn van Etten, et al.. (2020). Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. Radiotherapy and Oncology. 147. 75–83. 129 indexed citations

16.

Sclafani, Francesco, Ian Chau, David Cunningham, et al.. (2016). KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial. Annals of Oncology. 27. vi173–vi173. 1 indexed citations

17.

Cutsem, Eric Van, Hans Prenen, Geert D’Haens, et al.. (2015). A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Annals of Oncology. 26(10). 2085–2091. 35 indexed citations

18.

Dewdney, Alice, David Cunningham, Josep Tabernero, et al.. (2012). Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). Journal of Clinical Oncology. 30(14). 1620–1627. 287 indexed citations

19.

Macarulla, Teresa, Jaume Capdevila, José Manuel Pérez-García, et al.. (2009). New approaches and targets in advanced colorectal cancer. European Journal of Cancer. 45. 79–88. 4 indexed citations

20.

Capdevila, Jaume, Cristina Saura, Teresa Macarulla, et al.. (2007). Monoclonal antibodies in the treatment of advanced colorectal cancer. European Journal of Surgical Oncology. 33. S24–S34. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact